On December 26, at Glonghui, TJ DaRenTang (600329.SH) announced that the company would price the entire equity of its wholly-owned subsidiary Tianjin Zhongxin Pharmaceutical Co., Ltd. and inject it into the wholly-owned subsidiary of the company's controlling shareholder, Tianjin Pharmaceutical Group Co., Ltd., in the form of capital increase, and signed the "Capital Increase Agreement of TJ DaRenTang Group Co., Ltd. for Tianjin Tai Ping Pharmaceutical Co., Ltd.".

Recently, Tianjin Tai Ping Pharmaceutical Co., Ltd. and Tianjin Zhongxin Pharmaceutical Co., Ltd. have completed the industrial and commercial registration change procedures. Therefore, this Trade has been completed, with the company holding 43.35% equity in Tianjin Tai Ping Pharmaceutical Co., Ltd., and Tianjin Pharmaceutical Group Co., Ltd. holding 56.65% equity in Tianjin Tai Ping Pharmaceutical Co., Ltd.; Tianjin Tai Ping Pharmaceutical Co., Ltd. holds 100% equity in Tianjin Zhongxin Pharmaceutical Co., Ltd., thus the company indirectly holds 43.35% equity in Tianjin Zhongxin Pharmaceutical Co., Ltd. The company is a shareholder in Tianjin Tai Ping Pharmaceutical Co., Ltd. and Tianjin Zhongxin Pharmaceutical Co., Ltd.